Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
01:00am, Thursday, 09'th Jan 2025
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpo
Sanofi Down 10% in 3 Months: How Should You Play the Stock?
10:16am, Tuesday, 07'th Jan 2025
Sanofi's SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the past
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a targe
Gaming stocks likely to outperform semiconductor stocks in 2025
05:51am, Thursday, 02'nd Jan 2025
As 2025 draws near, the financial spotlight is moving from semiconductor companies to gaming stocks. Video game companies have been a bright spot for investors amid global unpredictability due to a sp
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
01:46pm, Monday, 23'rd Dec 2024
SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in infants and toddlers.
Sanofi initiates phase 3 program for PCV21 and expands collaboration with SK bioscience for next-generation pneumococcal conjugate vaccines
Presse release: Jean-Paul Kress to join Sanofi's Board of Directors
12:00pm, Thursday, 19'th Dec 2024
Jean-Paul Kress to join Sanofi's Board of Directors Paris, December 19, 2024. Sanofi's Board of Directors is pleased to welcome Jean-Paul Kress as an independent director as of January 1, 2025, replac
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
09:25am, Wednesday, 18'th Dec 2024
Treatment with a Sanofi-Teva-partnered experimental drug meets the primary goals in a mid-stage study for Ulcerative colitis and Crohn's disease indications.
Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn into More Strength?
07:36am, Wednesday, 18'th Dec 2024
Sanofi (SNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in th
Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's
02:25pm, Tuesday, 17'th Dec 2024
U.S.-traded shares of Teva Pharmaceuticals (TEVA) and Sanofi (SNY) took off Tuesday after the two drugmakers reported positive results from a study of their treatment for ulcerative colitis (UC) and C
TD says Spyre has 'superior TL1A program' after Teva data
02:18pm, Tuesday, 17'th Dec 2024
TD Cowen analyst Tyler Van Buren recommends buying shares of Spyre Therapeutics (SYRE) following the "impressive results" from Teva (TEVA) and Sanofi (SNY) in inflammatory bowel diseases. Similar to i
Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment
11:51am, Tuesday, 17'th Dec 2024
Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.
Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
09:16am, Tuesday, 17'th Dec 2024
On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA's SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn's disease (CD).
BrightInsight Expands Global Digital Partnership with Sanofi to Build Drug Companion Apps for its Major Specialty Therapies
08:30am, Tuesday, 17'th Dec 2024
BrightInsight announced an expanded global digital partnership with Sanofi to build branded patient apps to drive adoption, adherence, and persistence.
Teva, Sanofi say drug to treat IBD met primary targets
07:35am, Tuesday, 17'th Dec 2024
Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ulcerative colitis and Crohn's disease showed it had met primary goals.
